Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
Primary Purpose
Acne Vulgaris
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Benzoyl Peroxide
Moisturizing Lotion
Sponsored by
About this trial
This is an interventional treatment trial for Acne Vulgaris focused on measuring Acne
Eligibility Criteria
Inclusion Criteria:
- Healthy male or female subjects who are 18 to 35 years of age.
- Subjects are in good health and are free of any other facial skin disorders that may interfere with acne study assessments.
- Subjects have the willingness and ability to understand and provide informed assent/consent to participate in the study and are able to communicate with the investigator. Subjects are willing and able to follow all study directions and to commit to all follow-up visits for the duration of the study. In addition, subjects must be willing to accept the restrictions of the study.
- A minimum of 2 but no more than 30 inflammatory lesions (papules and pustules), relatively symmetrical in appearance on both sides of the face and a minimum of 2 but not more than 100 non-inflammatory lesions (open comedones and closed comedones) relatively symmetrical in appearance on both sides of the face.
- Ongoing oral medications (other than those specifically for acne) are acceptable provided subjects are on a stable regimen throughout the study and provided the medications are determined likely to not interfere with study assessments.
- Subjects will not use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave lotions) for the duration of the study.
- Subjects who agree not use any other acne treatment (including prescription and non-prescription medications) on the test site for the duration of the study.
- Subjects who agree not to change facial cosmetic products during the study.
- Subjects who agree to only use sunscreen/sunblock agents that are labeled as non-comedogenic.
Exclusion Criteria:
- Subjects or parents of subjects who are unable to understand the protocol or to give informed consent/assent.
- Subjects with mental illness.
- Subjects with no inflammatory acne.
- Subjects with any acne cysts or nodules.
- Subjects with acne conglobata, acne fulminans, secondary acne (e.g. Chloracne, drug-induced acne), or any acne requiring systemic treatment.
- Subjects with excessive facial hair that may interfere with study assessments.
- Subjects with other facial skin disorders that may interfere with study assessments.
- Subjects with a history of skin cancer or actinic keratosis.
- Subjects who have used tanning devices within one week prior to baseline study visit.
- Subjects who have applied any topical products (e.g. emollients, sunscreens) or any cosmetics to the face at least one hour prior to study assessments.
- Use of hormonal oral contraceptives for acne control or for less than 6 months prior to study baseline.
- Subjects with known allergies, a history of, or sensitive to salicylic acid, benzoyl peroxide or any of the test article components.
- Subjects using topical or systemic medication within 14 days before the study entry, which could interfere with study assessments. This includes but is not limited to the following: anti-inflammatory drugs (e.g. topical and systemic corticosteroids and systemic antihistamines), anti-acne drugs, topical and oral retinoids, topical antibacterial agents to the face, and any immunosuppressive drugs. Ongoing oral medications not expected to interfere with study assessments are allowed if the subject is on a stable regimen.
- Subjects who are currently enrolled in another clinical investigation or have been enrolled in an acne trial within a period of 30 days prior to enrollment in this study.
- Subjects who are pregnant or nursing.
- Subjects who require electrolysis, waxing, or depilatories on the face during conduct of the study.
- Subjects viewed by the investigator as not being able to complete the study.
Sites / Locations
- Northwestern University Department of Dermatology
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Benzoyl Peroxide
Benzoyl Peroxide plus moisturizing lotion
Arm Description
Benzoyl Peroxide (BP) 2.5%
Benzyol Peroxide 2.5% plus moisturizing lotion
Outcomes
Primary Outcome Measures
Subject Reported Change From Baseline Scale
-1=worse 0=unchanged
1=mild improvement
2=moderate improvement
3=clear
Secondary Outcome Measures
Full Information
NCT ID
NCT00558831
First Posted
November 13, 2007
Last Updated
August 28, 2017
Sponsor
Northwestern University
1. Study Identification
Unique Protocol Identification Number
NCT00558831
Brief Title
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
Official Title
A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the treatment of acne vulgaris.
Detailed Description
The purpose of this study is to compare the safety and efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for mild to moderate acne vulgaris.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
Acne
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Benzoyl Peroxide
Arm Type
Active Comparator
Arm Description
Benzoyl Peroxide (BP) 2.5%
Arm Title
Benzoyl Peroxide plus moisturizing lotion
Arm Type
Active Comparator
Arm Description
Benzyol Peroxide 2.5% plus moisturizing lotion
Intervention Type
Drug
Intervention Name(s)
Benzoyl Peroxide
Intervention Description
Benzoyl Peroxide 2.5%
Intervention Type
Drug
Intervention Name(s)
Moisturizing Lotion
Primary Outcome Measure Information:
Title
Subject Reported Change From Baseline Scale
Description
-1=worse 0=unchanged
1=mild improvement
2=moderate improvement
3=clear
Time Frame
baseline and 1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy male or female subjects who are 18 to 35 years of age.
Subjects are in good health and are free of any other facial skin disorders that may interfere with acne study assessments.
Subjects have the willingness and ability to understand and provide informed assent/consent to participate in the study and are able to communicate with the investigator. Subjects are willing and able to follow all study directions and to commit to all follow-up visits for the duration of the study. In addition, subjects must be willing to accept the restrictions of the study.
A minimum of 2 but no more than 30 inflammatory lesions (papules and pustules), relatively symmetrical in appearance on both sides of the face and a minimum of 2 but not more than 100 non-inflammatory lesions (open comedones and closed comedones) relatively symmetrical in appearance on both sides of the face.
Ongoing oral medications (other than those specifically for acne) are acceptable provided subjects are on a stable regimen throughout the study and provided the medications are determined likely to not interfere with study assessments.
Subjects will not use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave lotions) for the duration of the study.
Subjects who agree not use any other acne treatment (including prescription and non-prescription medications) on the test site for the duration of the study.
Subjects who agree not to change facial cosmetic products during the study.
Subjects who agree to only use sunscreen/sunblock agents that are labeled as non-comedogenic.
Exclusion Criteria:
Subjects or parents of subjects who are unable to understand the protocol or to give informed consent/assent.
Subjects with mental illness.
Subjects with no inflammatory acne.
Subjects with any acne cysts or nodules.
Subjects with acne conglobata, acne fulminans, secondary acne (e.g. Chloracne, drug-induced acne), or any acne requiring systemic treatment.
Subjects with excessive facial hair that may interfere with study assessments.
Subjects with other facial skin disorders that may interfere with study assessments.
Subjects with a history of skin cancer or actinic keratosis.
Subjects who have used tanning devices within one week prior to baseline study visit.
Subjects who have applied any topical products (e.g. emollients, sunscreens) or any cosmetics to the face at least one hour prior to study assessments.
Use of hormonal oral contraceptives for acne control or for less than 6 months prior to study baseline.
Subjects with known allergies, a history of, or sensitive to salicylic acid, benzoyl peroxide or any of the test article components.
Subjects using topical or systemic medication within 14 days before the study entry, which could interfere with study assessments. This includes but is not limited to the following: anti-inflammatory drugs (e.g. topical and systemic corticosteroids and systemic antihistamines), anti-acne drugs, topical and oral retinoids, topical antibacterial agents to the face, and any immunosuppressive drugs. Ongoing oral medications not expected to interfere with study assessments are allowed if the subject is on a stable regimen.
Subjects who are currently enrolled in another clinical investigation or have been enrolled in an acne trial within a period of 30 days prior to enrollment in this study.
Subjects who are pregnant or nursing.
Subjects who require electrolysis, waxing, or depilatories on the face during conduct of the study.
Subjects viewed by the investigator as not being able to complete the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Paller, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University Department of Dermatology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
We'll reach out to this number within 24 hrs